Roivant Sciences in exclusive joint venture talks with Arbutus; DBV gets green light to submit peanut allergy patch
→ Months after investing $116 million into Canada’s Arbutus $ABUS, Roivant Sciences confirmed early speculations that it’s exploring a joint venture deal. The companies spread word Wednesday that they have entered into a monthlong period of exclusive negotiations to jointly develop Arbutus’ nucleic acid delivery platform through a new company. Arbutus has built a rep for itself with both its in-house hepatitis B therapy and drugs from other companies, such as Alnylam’s patisiran, that utilize its delivery tech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.